Research Impact

h-index

N/A

Research impact score

Publications

0

Total publications

Trial Results

0

Published trial results

Citations

0

Total citations

Drug Portfolio

MIXED(19)
DRUG(1)
BIOLOGICAL(1)
Nivolumab
2 trials
phase_1phase_2
md-anderson-cancer-center
Fludarabine
2 trials
phase_2
md-anderson-cancer-center
Ipilimumab
2 trials
phase_1phase_2
md-anderson-cancer-center
Quality-of-Life Assessment
2 trials
phase_2
md-anderson-cancer-center
Lenvatinib
1 trial
phase_2
md-anderson-cancer-center
Pembrolizumab
1 trial
phase_2
md-anderson-cancer-center
Interleukin-2
1 trial
phase_2
md-anderson-cancer-center
Autologous Tumor Infiltrating Lymphocytes MDA-TIL
1 trial
phase_2
md-anderson-cancer-center

+9 more interventions

17 unique interventions3 categories

Analytics

Trial Phases

Phase 13
Phase 26

Trial Status

Completed3
Terminated2
Other2

Role Distribution

Principal Investigator7
PI Rate100%

Activity Timeline

Clinical Trials (7)

NCT05114421Phase 2Active Not Recruiting
Pembrolizumab and Lenvatinib for the Treatment of Serous Ovarian Cancer Patients
High Grade Fallopian Tube Serous AdenocarcinomaHigh Grade Ovarian Serous AdenocarcinomaPeritoneal High Grade Serous Adenocarcinoma+3 more
PrincipalinvestigatorStart date: 2021-11-09
NCT04019288Phase 1/2Terminated
AVB-S6-500 and Durvalumab in Treating Patients With Platinum-Resistant or Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Platinum-Resistant Fallopian Tube CarcinomaPlatinum-Resistant Ovarian CarcinomaPlatinum-Resistant Primary Peritoneal Carcinoma+6 more
PrincipalinvestigatorStart date: 2019-12-03
NCT03610490Phase 2Terminated
Autologous Tumor Infiltrating Lymphocytes MDA-TIL in Treating Patients With Recurrent or Refractory Ovarian Cancer, Colorectal Cancer, or Pancreatic Ductal Adenocarcinoma
Malignant Solid NeoplasmMetastatic Colorectal AdenocarcinomaMetastatic Ovarian Carcinoma+9 more
PrincipalinvestigatorStart date: 2018-10-16
NCT03508570Phase 1Completed
Nivolumab With or Without Ipilimumab in Treating Patients With Recurrent or High Grade Gynecologic Cancer With Metastatic Peritoneal Carcinomatosis
Malignant Peritoneal NeoplasmMalignant Retroperitoneal NeoplasmMetastatic Cervical Carcinoma+31 more
PrincipalinvestigatorStart date: 2018-09-21
NCT03318900Phase 1/2Completed
T-Cell Infusion, Aldesleukin, and Utomilumab in Treating Patients With Recurrent Ovarian Cancer
COL6A3 PositiveHLA-A*0201 Positive Cells PresentPRAME Positive+1 more
PrincipalinvestigatorStart date: 2018-09-04
NCT03449108Phase 2Active Not Recruiting
LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas
Bone SarcomaDedifferentiated ChondrosarcomaGiant Cell Tumor of Bone+13 more
PrincipalinvestigatorStart date: 2018-04-27
NCT03026062Phase 2Completed
Durvalumab and Tremelimumab in Treating Participants With Recurrent or Refractory Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Platinum-Resistant Fallopian Tube CarcinomaPlatinum-Resistant Ovarian CarcinomaPlatinum-Resistant Primary Peritoneal Carcinoma+6 more
PrincipalinvestigatorStart date: 2017-05-18

Research Network

Collaboration Network

1 collaborators·0 connections
Network Legend
KOL
Current Investigator
CO
High-influence Collaborator
CO
Collaborator
Click: view details
Double-click: go to profile
Drag: move node

Similar Key Opinion Leaders

Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.

10 similar investigators found

Heinz-Josef Lenz, MD

University of Southern California

Related
13 trials

Shared therapeutic areas:

Refractory Colorectal CarcinomaStage IV Colorectal Cancer AJCC v8Stage IVA Colorectal Cancer AJCC v8+2 more

Worked with same sponsors:

Bristol-Myers SquibbNational Cancer Institute (NCI)
Similarity Score2%

Lei Li, M.D.

Peking Union Medical College Hospital

Related
46 trials

Shared therapeutic areas:

Recurrent Cervical CarcinomaMetastatic Cervical CarcinomaRecurrent Ovarian Carcinoma
Similarity Score1%

Claudia Valverde

Hospital Universitari Vall d'Hebrón

Related
3 trials

Shared therapeutic areas:

SarcomaBone Sarcoma
Similarity Score1%

Josefina Cruz

Hospital Universitario de Canarias

Related
3 trials

Shared therapeutic areas:

SarcomaBone Sarcoma
Similarity Score1%

Javier Martín Broto

Hospital Universitario Fundación Jiménez Díaz

Related
5 trials

Shared therapeutic areas:

SarcomaBone Sarcoma
Similarity Score1%

Andrés Redondo

Hospital Universitario La Paz

Related
3 trials

Shared therapeutic areas:

SarcomaBone Sarcoma
Similarity Score1%

Michael B Gill

Power Life Sciences Inc.

Related
105 trials

Shared therapeutic areas:

SarcomaTriple Negative Breast Neoplasms
Similarity Score1%

Brigitte C Widemann, M.D.

National Cancer Institute (NCI)

Related
19 trials

Shared therapeutic areas:

Sarcoma

Worked with same sponsors:

National Cancer Institute (NCI)
Similarity Score0%

Lung-Ji Chang, PhD

Shenzhen Geno-Immune Medical Institute

Related
18 trials

Shared therapeutic areas:

Sarcoma
Similarity Score0%

Scot C. Remick, MD

Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center

Related
13 trials

Shared therapeutic areas:

Sarcoma

Worked with same sponsors:

National Cancer Institute (NCI)
Similarity Score0%

Publications (0)

No publications found for this investigator.

Clinical Trials (7)

Showing 7 of 7 trials

NCT05114421Phase 2PrincipalInvestigator

Pembrolizumab and Lenvatinib for the Treatment of Serous Ovarian Cancer Patients

High Grade Fallopian Tube Serous AdenocarcinomaHigh Grade Ovarian Serous AdenocarcinomaPeritoneal High Grade Serous Adenocarcinoma+3 more
Active Not Recruiting
NCT04019288Phase 1/2PrincipalInvestigator

AVB-S6-500 and Durvalumab in Treating Patients With Platinum-Resistant or Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Platinum-Resistant Fallopian Tube CarcinomaPlatinum-Resistant Ovarian CarcinomaPlatinum-Resistant Primary Peritoneal Carcinoma+6 more
Terminated
NCT03610490Phase 2PrincipalInvestigator

Autologous Tumor Infiltrating Lymphocytes MDA-TIL in Treating Patients With Recurrent or Refractory Ovarian Cancer, Colorectal Cancer, or Pancreatic Ductal Adenocarcinoma

Malignant Solid NeoplasmMetastatic Colorectal AdenocarcinomaMetastatic Ovarian Carcinoma+9 more
Terminated
NCT03508570Phase 1PrincipalInvestigator

Nivolumab With or Without Ipilimumab in Treating Patients With Recurrent or High Grade Gynecologic Cancer With Metastatic Peritoneal Carcinomatosis

Malignant Peritoneal NeoplasmMalignant Retroperitoneal NeoplasmMetastatic Cervical Carcinoma+31 more
Completed
NCT03318900Phase 1/2PrincipalInvestigator

T-Cell Infusion, Aldesleukin, and Utomilumab in Treating Patients With Recurrent Ovarian Cancer

COL6A3 PositiveHLA-A*0201 Positive Cells PresentPRAME Positive+1 more
Completed
NCT03449108Phase 2PrincipalInvestigator

LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas

Bone SarcomaDedifferentiated ChondrosarcomaGiant Cell Tumor of Bone+13 more
Active Not Recruiting
NCT03026062Phase 2PrincipalInvestigator

Durvalumab and Tremelimumab in Treating Participants With Recurrent or Refractory Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Platinum-Resistant Fallopian Tube CarcinomaPlatinum-Resistant Ovarian CarcinomaPlatinum-Resistant Primary Peritoneal Carcinoma+6 more
Completed

All 7 trials loaded